Sector News

Novo Nordisk chief Sørensen tops world's-best CEO ranking

October 13, 2015
Life sciences

This year, the world’s best-performing CEO also happens to be a pharma exec. He’s doesn’t hail from Big Pharma, or Big Biotech for that matter. He’s far from the industry’s highest-paid; in fact, he’s never made FiercePharma’s CEO pay list.

Perhaps he should. According to the Harvard Business Review, which ranks CEOs annually, Novo Nordisk chief Lars Rebien Sørensen tops the charts, not just for his company’s financial prowess, but also under environmental, social and governance measures.

Since Sørensen took the reins at Novo in 2000, the diabetes-focused company has delivered more than tenfold returns on shareholders’ money. Adjusted for the drug industry, that’s fifteenfold, the HBR calculates. Its market cap has grown by $169 billion; as of Tuesday, Novo’s market cap amounted to more than $356 billion.

All those numbers put Sørensen in 6th place out of the 907 chief executives HBR weighed. And that accounted for four-fifths of his total score. The other one-fifth was a “softer” measure of leadership, based on environmental and social responsibility, plus governance assessments. By those lights, Sørensen and Novo came in 15th.

For several years, the Danish drugmaker has reported its results in light of a “triple bottom line,” that attempts to measure Novo’s performance as environmental caretakers, as an employer and as a corporate citizen. It takes into account everything from the company’s wind power initiatives to its contributions to the World Diabetes Foundation, which it created to build diabetes care infrastructure and capacity in countries where the disease is poorly treated.

That explains why Sørensen climbed up HBR’s rankings for 2015. Last year, the review focused only on the financials and he came in 6th; this year, it added the other assessments. In 2013, the Novo chief captured 20th place.

To Sørensen, paying attention to those so-called “softer” measures delivers hard returns in the long term. “Corporate social responsibility is nothing but maximizing the value of your company over a long period,” Sørensen told HBR. “In the long term, social and environmental issues become financial issues.” For instance, industrial pollution can trigger stricter regulations that cost money, he said.

Last year, pharma’s highest-ranked CEO on the HBR list was Gilead Sciences’ John Martin, in 2nd place behind Amazon’s Jeff Bezos. Martin now sits in 42nd place, putting him in third place in the drug business. Biogen chief George Scangos was Sørensen’s runner-up in 8th place. The only Big Pharma chief to make the top-100 cut was Bristol-Myers Squibb’s Lamberto Andreotti, who handed the CEO reins to Giovanni Caforio in May.

Valeant Pharmaceuticals CEO J. Michael Pearson, who ranked among last year’s top 10, fell off the list entirely. Allergan chief David Pyott, also among last year’s top 10, was replaced by current CEO Brent Saunders when Actavis and Allergan merged last year.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”